CTRL Therapeutics

CTRL Therapeutics (cTRL Tx) is a Chicago-based preclinical biotechnology company developing next-generation cell therapies for solid tumors. The company harnesses circulating tumor-reactive lymphocytes (cTRLs) - a rare, potent T cell population found in the blood and naturally equipped to fight cancer - to engineer polyclonal cell therapies that avoid invasive tumor-tissue surgery. From a single blood draw, CTRL's proprietary IsoQore cell-sorting platform isolates millions of migratory, tumor-reactive cTRLs via novel markers, aiming to simplify the discovery, manufacturing and administration of solid-tumor cell therapy. CTRL launched in 2023 with a $10M seed financing led by General Catalyst, with participation from Intermountain Health and FACIT. This profile was surfaced as a General Catalyst portfolio company and added to the API Evangelist network; the company operates a corporate website and publishes no public developer API surface.

CTRL Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Cell Therapy, Oncology, and Cancer.

CTRL Therapeutics’ developer surface includes product news and 7 more developer resources.

🌐 Visit website 📡 Source on GitHub

7.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechnologyCell TherapyOncologyCancerHealthcareLife SciencesPharmaceuticals

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 7.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/ctrl-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Company 5

The organization behind the API

Website

About

News

Careers

LinkedIn

Other 1

Properties that don't map to a standard resource type

Team

Team

Source (apis.yml)

aid: ctrl-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/ctrl-therapeutics.png
name: CTRL Therapeutics
description: CTRL Therapeutics (cTRL Tx) is a Chicago-based preclinical biotechnology company developing next-generation cell
  therapies for solid tumors. The company harnesses circulating tumor-reactive lymphocytes (cTRLs) - a rare, potent T cell
  population found in the blood and naturally equipped to fight cancer - to engineer polyclonal cell therapies that avoid
  invasive tumor-tissue surgery. From a single blood draw, CTRL's proprietary IsoQore cell-sorting platform isolates millions
  of migratory, tumor-reactive cTRLs via novel markers, aiming to simplify the discovery, manufacturing and administration
  of solid-tumor cell therapy. CTRL launched in 2023 with a $10M seed financing led by General Catalyst, with participation
  from Intermountain Health and FACIT. This profile was surfaced as a General Catalyst portfolio company and added to the
  API Evangelist network; the company operates a corporate website and publishes no public developer API surface.
url: https://raw.githubusercontent.com/api-evangelist/ctrl-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- general-catalyst
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Biotechnology
- Cell Therapy
- Oncology
- Cancer
- Healthcare
- Life Sciences
- Pharmaceuticals
apis: []
common:
- type: DomainSecurity
  url: security/ctrl-therapeutics-domain-security.yml
- type: Website
  url: https://ctrl-tx.com
- type: About
  url: https://ctrl-tx.com/our-science
- type: Team
  url: https://ctrl-tx.com/our-team
- type: News
  url: https://ctrl-tx.com/news
- type: Contact
  url: https://ctrl-tx.com/contact
- type: Careers
  url: https://ctrl-tx.com/join-us
- type: LinkedIn
  url: https://www.linkedin.com/company/ctrl-therapeutics/
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence